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SARS-CoV-2 is the recently discovered virus which has resulted in 
the pandemic illness known as Coronavirus disease 2019 (COVID-
19)1. It is from the family of viruses known as Coronaviridae, which 
were also responsible for Severe Acute Respiratory Syndrome 
(SARS), which originated in China in 2002, and Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV) in 2012.  It is 
thought to be a zoonosis, possibly originating in bats, which has 
undergone intra-species transfer between intermediary hosts and 
humans.  
The high infectivity of SARS-Cov-2 is a major contributor to this 
pandemic. Infectivity of a pathogen can be quantified as the basic 
reproduction number (R0). This is  the number of cases directly 
generated by one case in a population where all individuals are 
susceptible to infection2. Estimates suggest that, for SARS-CoV-2, 
R0 is  >2.43-5; thus for every case which occurs, on average more 
than 2 additional cases are generated in a susceptible population, in 
the absence of adequate measures such as isolation.  For comparison, 
seasonal flu has an R0 of approximately 1.26.  
A major issue with regards to infectivity, particularly when 
considering implementing targeted measures to reduce spread, is the 
potential for transmission by asymptomatic patients. The risk of 
contagion presented by asymptomatic or mildly symptomatic cases 
of SARS-CoV-2 is unclear. The majority of descriptive papers 
investigating mild symptoms are focused on inpatients 7, specific 
populations 8 or modelling 9. Although there are suggestions of 
lower infectivity amongst asymptomatic patients 9, this has not been 
confirmed. Estimates for the proportion of asymptomatic patients 
infected with SARS-CoV-2 in different populations range between 
7% to 80% 10-12, with a substantial proportion of transmission 
occurring prior to illness onset 13 14. 
 
Protecting healthcare workers is an imperative 15, particularly for  
those who work in close proximity to patients’ faces  including 
ophthalmologists. Regularly updated recommendations have been 
issued to reduce patient contact and adjust patient flow for 
ophthalmology during the pandemic 16, 17. Gloves, disposable aprons, 
eye protection, fluid resistant type IIR surgical masks and slit lamp 
guards are recommended as Personal Protective Equipment (PPE) 
for ophthalmic clinic assessment by the Royal College of 
Ophthalmologists 18. Additionally, the optimal type of respiratory 
protective masks remains a matter of important debate and varies. 
Within Europe, filtering face piece respirator masks (FFP) are 
graded based on filter efficacy and face adhesion17: filtering face 
piece (FFP) 1, 2 and 3 are able to filter with efficacies of 80%, 94%, 
and 99% respectively14, 19. Within the USA, FFP2 masks are termed 
N95. Guidelines for mask use vary worldwide. The European Centre 
for Disease and Prevention (ECDC) 17 and the US CDC 20 
recommend FFP2 masks (N95) for care of patients with COVID-19, 
whilst the WHO recommends standard surgical masks 21. Within the 
UK, Public Health England regularly update their guidance with 
regard to PPE 22.  
A major discriminator in determining mask use is whether staff are 
exposed to aerosols. SARS-CoV-2 likely binds in the first instance 
to nasal epithelial cells before migrating through the bronchial tree 
where it preferentially infects alveolar type II lung cells leading to a 
viral laden mucus that passes up the respiratory tract23. Transmission 
can occur through droplets and viral laden aerosols generated from 
breathing, coughing and sneezing and, in the healthcare 
environment, from procedures known as aerosol generating 
procedures (AGPs). Large droplets are propelled through the air and 
can cause infection through a contact mechanism with or without 
fomites. 12, 24. Small droplets, may evaporate to create an aerosol; 
defined as small particles (less than 10 microns diameter) in 
suspension in gas25. Aerosols can remain suspended in the air for 
long periods, with the potential of travelling large distances (metres) 
transmitting disease by being inhaled and penetrating deeply into the 
respiratory tract. Symptomatic patients with SARS tend to develop 
lower respiratory tract infections, suggesting aerosol transmission is 
important26. Numerous studies have demonstrated the presence of 
influenza virus in exhaled breath 27, 28. SARS-CoV-2 has been 
demonstrated in tears 29, and causes ocular signs in patients with 
COVID-19 30, although infrequently. Therefore, there is a potential 
for ocular mucosal transmission, though this is likely to be much less 
than via the respiratory mucosa. Viral presence in intraocular 




In AGPs, aerosols can be generated by applying sufficient 
mechanical energy (from high speed devices) to an air-water 
interface to form fine droplets. They can be generated from the 
evaporation of larger droplets (<100 microns) as they settle in air 
and also by fragmentation of large droplets once they dry on 
surfaces and are later resuspended.  
AGPs involving the upper respiratory tract including endotracheal 
intubation and airway suction are recognised to be associated with 
an increased risk of SARS transmission to health care workers31 
including SARS-CoV-232 but the risks from other anatomical sites 
are less clear. PHE has also included “surgery with high speed 
devices” as AGPs 22 There are reports of high speed drills and 
hydro-surgical debridement used in spinal surgery generating 
aerosols33, 34, and viable viral pathogen on dental drills35. Mask use 
in the context of AGP is more stringent. To try to avoid inhalation of 
small viral laden particles in the air requires a tight seal around the 
edge of the mask and greater filtering capacity. However, the exact 
requirements mandated vary throughout the world. Chinese 
physicians suggest that in addition to N95 masks, that “Full-face 
respiratory protective devices or powered air-purifying respirator” 
be employed 36. In the UK, PHE recommends single use FFP masks 
22.  
There is, as yet, no robust evidence on the AGP nature of our 
intraocular surgical instruments. The frequency of modern 
phacoemulsification hand pieces exceeds 40kHz and modern pars 
plana vitrectomy (PPV) handpieces have cut rates in excess of 5000 
cuts per minute. These can therefore certainly be considered “high 
speed” surgical devices. In addition, it is possible that other 
vitreoretinal surgical manoeuvres could generate droplets or aerosol, 
such as fluid-air exchange. During the SARS-CoV-2 pandemic, it is 
likely that pars plana vitrectomy for rhegmatogenous retinal 
detachment will be the most commonly performed intraocular 
surgery. The length of surgery in close proximity to patient airways 
poses further risk. To minimize risk of transmission, we as the Royal 
College of Ophthalmologists and the British & Eire Association of 
Vitreoretinal Surgeons (BEAVRS) have issued specific guidelines 
regarding these procedures 18. These include reducing surgical 
volume, minimizing staff presence and potential use of additional 
surgical drapes to minimize aerosol transmission. In particular, 
despite the absence of complete evidence at present, but based on the 
balance of risk and probability, we consider PPV should be treated 
as an AGP. We therefore advise appropriate  PPE including FFP3 
masks for surgeon and nurses during these procedures. Given the 
asymptomatic burden of SARS-Cov-2, we have recommended these 
precautions should be applied regardless of patients’ symptoms 18. 
We are pleased to note that the American Society of Retinal 
Specialists has more recently made similar recommendations 37 
embodying a wider consensus. Recommendations will continue to 
adapt, reflecting the impact of social measures, new scientific 
evidence, more reliable viral testing and population healthcare 
needs.  
 
The increased use of PPE worldwide is inevitably leading to supply 
shortages. Guidance from PHE continues to be updated in response 
to this issue, with advice now on reuse of gowns38. In the long term 
however there needs to be close coordination between medical, 
engineering, research and manufacturing communities to evaluate 
and extend the options for recycling and re-sterilizing PPE on a large 
scale whilst maintaining anti-viral properties and protection. This 
needs to be undertaken multilaterally and urgently as the precious 
resource of PPE is shrinking.  
 
The anxieties during this pandemic will not easily be allayed. 
However by employing cautious clinical principles and ensuring 
high standard of protection, we hope to minimize the risk to 
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